Does clinical-CT 'mismatch' predict early response to treatment with recombinant tissue plasminogen activator?

Cerebrovascular Diseases

Volumn 22, Issue 5-6, 2006, Pages 384-388

  Choi, John Y ^a,d   Pary, Jennifer K ^a   Alexandrov, Andrei V ^a   Molina, Carlos A ^b   Garami, Zsolt ^a   Malkoff, Marc D ^a   Rubiera, Marta ^b   Shaltoni, Hashem M ^a   Moye, Lemuel A ^c   Grotta, James C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d 7044 MSB ^*  (United States)

Author keywords

Cerebral ischemia; Mismatch, clinical CT findings; Outcomes; Thrombolysis

Indexed keywords

ALTEPLASE;

ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; SAMPLE SIZE; SCORING SYSTEM; STROKE PATIENT; TREATMENT RESPONSE;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INFUSIONS, INTRAVENOUS; ODDS RATIO; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33750594436     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094856     Document Type: Article

References (20)

1. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, Broderick JP, Levine SR, Frankel MP, Horowitz SH, et al: Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000;55:1649-1655.
2. Lyden P: Early major ischemic changes on computed tomography should not preclude use of tissue plasminogen activator. Stroke 2003;34:821-822.
3. von Kummer R: Early major ischemic changes on computed tomography should preclude use of tissue plasminogen activator. Stroke 2003;34:820-821.
4. Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, Haley EC Jr, Brott TG, Broderick JP, Horowitz S, et al: Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001;286:2830-2838.
5. Grotta JC, Chiu D, Lu M, Patel S, Levine SR, Tilley BC, Brott TG, Haley EC Jr, Lyden PD, Kothari R, et al: Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke 1999;30:1528-1533.
6. Pexman JH, Barber PA, Hill MD, Sevick RJ, Demchuk AM, Hudon ME, Hu WY, Buchan AM: Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol 2001;22:1534-1542.
7. Barber PA, Demchuk AM, Zhang J, Buchan AM: Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000;355:1670-1674.
8. The NINDS t-PA Stroke Study Group: Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109-2118.
9. Hill MD, Rowley HA, Adler F, Eliasziw M, Furlan A, Higashida RT, Wechsler LR, Roberts HC, Dillon WP, Fischbein NJ, et al: Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS. Stroke 2003;34:1925-1931.
10. Grotta J: NIHSS/EIC mismatch explains the >1/3 MCA conundrum. Stroke 2003;34:e148-e149; author reply e148-e149.
11. Alexandrov AV, Wojner AW, Grotta JC: CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke. J Neuroimaging 2004;14:108-112.
12. Alexandrov AVM, Carlos A, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saqqur M, Demchuk AM, Moye LA, Hill MD, Wojner AW: Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004;351:2170-2178.
13. Burgin WS, Malkoff M, Felberg RA, Demchuk AM, Christou I, Grotta JC, Alexandrov AV: Transcranial Doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke. Stroke 2000;31:1128-1132.
14. Tomsick T, Brott T, Barsan W, Broderick J, Haley EC, Spilker J, Khoury J: Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultra-early thrombolytic therapy. AJNR Am J Neuroradiol 1996;17:79-85.
15. Felberg RA, Okon NJ, El-Mitwalli A, Burgin WS, Grotta JC, Alexandrov AV: Early dramatic recovery during intravenous tissue plasminogen activator infusion: clinical pattern and outcome in acute middle cerebral artery stroke. Stroke 2002;33:1301-1307.
16. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
17. Broderick JP, Lu M, Kothari R, Levine SR, Lyden PD, Haley EC, Brott TG, Grotta J, Tilley BC, Marler JR, et al: Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 2000;31:2335-2341.
18. DEFUSE Investigators: Late infusion of tPA after stroke associated with significant success rate: DEFUSE Trial; in 31st Int Stroke Conf, Kissimmee, Feb 2006.
19. Davalos A, Blanco M, Pedraza S, Leira R, Castellanos M, Pumar JM, Silva Y, Serena J, Castillo J: The clinical-DWI mismatch: a new diagnostic approach to the brain tissue at risk of infarction. Neurology 2004;62:2187-2192.
20. Kidwell CS, Saver JL, Mattiello J, Starkman S, Vinuela F, Duckwiler G, Gobin YP, Jahan R, Vespa P, Kalafut M, et al: Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol 2000;47:462-469.